Malaria Research Advances on Multiple Fronts as Drug Resistance Grows and New Vaccine Technologies Emerge

Malaria research is advancing rapidly as the deadly pathogen Plasmodium falciparum develops increasingly sophisticated, multi-drug genetic resistance. A genetic analysis of 605 Ethiopian samples revealed widespread resistance markers to both discontinued drugs like chloroquine and current frontline therapies. To counter this threat, scientists are developing innovative solutions. Researchers at the Ragon Institute successfully engineered peptide add-ons that expand the antibody response of current vaccines to three distinct regions of the parasite's PfCSP protein. Concurrently, the FDA's landmark approval of Moderna's mFlusiva, the first mRNA flu vaccine, has strengthened the outlook for deploying mRNA technology against malaria.

Plasmodium falciparum drug resistance evolution

• ▪Plasmodium falciparum has developed resistance to almost all antimalarial treatments developed over the last 70 years, including artemisinin, which was discovered in the 1970s.
• ▪Artemisinin partial resistance in Plasmodium falciparum was first identified in Southeast Asia over 15 years ago and has since been reported in several locations in Africa.
• ▪The malaria parasite Plasmodium falciparum is stockpiling genetic adaptations linked to resistance against multiple drug treatments, according to a study published in Nature Microbiology.

Ethiopian malaria parasite genetic analysis

• ▪A genetic analysis of 605 Plasmodium falciparum samples collected from 15 Ethiopian districts between 2019 and 2023 revealed that chloroquine resistance markers remain present in 61.2 percent of 492 successfully classified samples.
• ▪The main genetic marker for artemisinin partial resistance was detected in 10 percent of 572 Ethiopian Plasmodium falciparum samples, reaching as high as 48.6 percent in one district.
• ▪A genetic pattern associated with reduced sensitivity to lumefantrine was found in 93 percent of 483 classified Plasmodium falciparum samples from Ethiopia.
• ▪Researchers found that sulfadoxine-pyrimethamine resistance markers were present in 42.8 percent of 453 Ethiopian Plasmodium falciparum samples, despite the treatment being discontinued in Ethiopia in 2005.

mRNA malaria vaccine development

• ▪Following the FDA approval of its mRNA flu vaccine mFlusiva, researchers see potential for Moderna to develop mRNA-based vaccines against fast-changing diseases like malaria and HIV.
• ▪The mRNA technology used in Moderna's vaccines prompts the body to produce its own antigens to trigger an immune response against targeted pathogens.

PfCSP protein targeting strategies

• ▪A study from the Batista Lab published in the Journal of Experimental Medicine shows that current malaria vaccines RTS,S and R21 only target the major repeat region of the PfCSP protein.
• ▪An investigation by the Batista Lab and collaborating institutions revealed that how an antibody binds to the PfCSP protein matters more for protection than the absolute strength of the binding grip.
• ▪Researchers engineered a combination vaccine adding two short peptides representing the minor repeat and junction regions of PfCSP to the R21-style protein, which successfully engaged three antibody targets and reduced liver parasites in mice.

Moderna mFlusiva FDA approval

• ▪On August 5, 2026, the U.S. Food and Drug Administration approved Moderna's mFlusiva, the country's first mRNA-based seasonal influenza vaccine.
• ▪In a late-stage clinical trial involving over 40,000 older adults, Moderna's mFlusiva was 26.6 percent more effective than a standard traditional flu shot.
• ▪Moderna's mFlusiva received traditional FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older, with a confirmatory clinical trial required for the older group.